Jaydira Del Rivero, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 13C434
- Bethesda, MD 20892
Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma.
Areas of Expertise
1) neuroendocrine neoplasms 2) neuroendocrine tumors 3) neuroendocrine carcinomas 4) pheochromocytoma/paraganglioma 5) adrenocortical carcinoma
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Neuroendocrine neoplasms (NENs) are a rare spectrum of malignant neoplasms from low-grade neuroendocrine tumors to high- grade neuroendocrine carcinomas. A variety of therapeutic options are available for patients with advanced NETs, however, when to apply a given option, what combination therapeutic approach should be used, how long treatment should be continued should be used is unclear and controversial and further studies are warranted to develop more effective therapies. Our focus is to better understand the genetic and epigenetic underpinnings for NENs, development of pre-clinical models, determine predictive biomarkers for DNA-targeted agents: DNA alkylators, TOP1 and TOP2 inhibitors and DNA replication inhibitors as novel targets for NENs.
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors
Neuroendocrine Tumors-Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence
PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies
Jaydira Del Rivero, M.D.
Dr. Del Rivero earned her medical degree from the Faculty of Medicine at the University of Veracruz in Veracruz, Mexico. Dr. Del Rivero then completed her internal medicine residency at Woodhull Medical and Mental Health Center/New York University (NYU)-Langone Medical Center in Brooklyn. Following residency, she completed a fellowship in endocrinology at the Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Child Health and Human Development (NICHD), and the National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) focusing on the managment of all endocrine tumors, such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer, pheochromocytoma/paraganglioma and other endocrine malignancies. She subsequently completed a second fellowship in oncology at the National Cancer Institute. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Oncology.
Dr. Del Rivero serves on the Board of Directors of the North American Neuroendocrine Tumor Society (NANETS) and serves on the Guidelines Committee.
Patient Education Day
August 15, 2020
Dr. Del Rivero participated in the Society of Nuclear Medicine & Molecular Imaging's Annual Patient Education Day. She was a speaker in a webinar about neuroendocrine tumors. Learn more…
A Destiny in Neuroendocrine Oncology
The NIH Catalyst
Jaydira del Riverois one of the world’s few specialists in rare cancers that originate in the body’s neuroendocrine system, which is made up of specialized cells that make hormones in response to neurological signals. Her goal is to treat these tumors holistically—using a biological approach as well as taking the whole patient into consideration. Read more...